Scholarlink

Purpose <p>With growing interest in surgical de-escalation for breast cancer, tumor bed biopsy (TBB) after neoadjuvant chemotherapy (NACT) has been proposed as a tool to predict pathological complete response (pCR). This meta-analysis assessed the diagnostic accuracy and clinical applicability of TBB in breast cancer patients achieving complete clinical response (cCR) post-NACT.</p> Methods <p>PubMed, Embase, and online clinical trial registries were systematically searched up to April 2025 for studies evaluating TBB in cCR patients after NACT. Pooled sensitivity, specificity and false-negative rate (FNR) were calculated using a random-effects model. Heterogeneity was quantified using the <i>I</i><sup>2</sup> statistic.</p> Results <p>Eight studies met inclusion criteria. Pooled sensitivity was 0.58 (95% CI 0.51–0.65), specificity was 1.00 (95% CI 0.99–1.00) and the pooled false-negative rate was (42%, 95% CI 35–49%) with <i>I</i><sup>2</sup> values (65.8% for sensitivity; 0% for specificity).</p> Conclusion <p>In this meta-analysis limited to patients achieving clinical complete response after neoadjuvant chemotherapy, tumor bed biopsy demonstrated excellent specificity but suboptimal sensitivity with an unacceptably high false-negative rate. These findings indicate that a negative tumor bed biopsy cannot reliably confirm pathological complete response and therefore cannot replace standard surgical excision at present. While tumor bed biopsy may help identify residual disease, its current diagnostic performance does not support its use as a standalone tool for surgical de-escalation, underscoring the need for further refinement and prospective validation before clinical adoption.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic accuracy of tumor bed biopsy for predicting pathological complete response in breast cancer patients achieving clinical complete response after neoadjuvant chemotherapy: a meta-analysis

  • 期刊论文

  • 发表日期：

    2026年2月5日

查看全文
  • Garvit Garg,
  • S. Bharath,
  • Abhishek Krishna,
  • Shivank Sethi,
  • Vishesh Agrawal,
  • Goonj Johri,
  • Sanjay Kumar Yadav,
  • Dhananjaya Sharma

摘要

Purpose

With growing interest in surgical de-escalation for breast cancer, tumor bed biopsy (TBB) after neoadjuvant chemotherapy (NACT) has been proposed as a tool to predict pathological complete response (pCR). This meta-analysis assessed the diagnostic accuracy and clinical applicability of TBB in breast cancer patients achieving complete clinical response (cCR) post-NACT.

Methods

PubMed, Embase, and online clinical trial registries were systematically searched up to April 2025 for studies evaluating TBB in cCR patients after NACT. Pooled sensitivity, specificity and false-negative rate (FNR) were calculated using a random-effects model. Heterogeneity was quantified using the I2 statistic.

Results

Eight studies met inclusion criteria. Pooled sensitivity was 0.58 (95% CI 0.51–0.65), specificity was 1.00 (95% CI 0.99–1.00) and the pooled false-negative rate was (42%, 95% CI 35–49%) with I2 values (65.8% for sensitivity; 0% for specificity).

Conclusion

In this meta-analysis limited to patients achieving clinical complete response after neoadjuvant chemotherapy, tumor bed biopsy demonstrated excellent specificity but suboptimal sensitivity with an unacceptably high false-negative rate. These findings indicate that a negative tumor bed biopsy cannot reliably confirm pathological complete response and therefore cannot replace standard surgical excision at present. While tumor bed biopsy may help identify residual disease, its current diagnostic performance does not support its use as a standalone tool for surgical de-escalation, underscoring the need for further refinement and prospective validation before clinical adoption.